Park West Asset Management Llc Buys 400,000 Shares of Kindred Biosciences Inc (KIN) Stock

Kindred Biosciences Inc (NASDAQ:KIN) major shareholder Park West Asset Management Llc bought 400,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 15th. The shares were purchased at an average cost of $6.60 per share, for a total transaction of $2,640,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Park West Asset Management Llc also recently made the following trade(s):

  • On Monday, March 13th, Park West Asset Management Llc bought 4,200 shares of Kindred Biosciences stock. The shares were purchased at an average cost of $6.20 per share, for a total transaction of $26,040.00.
  • On Thursday, March 9th, Park West Asset Management Llc bought 18,066 shares of Kindred Biosciences stock. The shares were purchased at an average cost of $6.08 per share, for a total transaction of $109,841.28.
  • On Friday, January 13th, Park West Asset Management Llc bought 1,690,000 shares of Kindred Biosciences stock. The shares were purchased at an average cost of $6.20 per share, for a total transaction of $10,478,000.00.
  • On Monday, January 9th, Park West Asset Management Llc bought 131,500 shares of Kindred Biosciences stock. The shares were purchased at an average cost of $5.30 per share, for a total transaction of $696,950.00.
  • On Friday, January 6th, Park West Asset Management Llc bought 110,617 shares of Kindred Biosciences stock. The shares were purchased at an average cost of $5.10 per share, for a total transaction of $564,146.70.

Shares of Kindred Biosciences Inc (NASDAQ:KIN) opened at 7.00 on Tuesday. The firm’s market cap is $154.49 million. Kindred Biosciences Inc has a 52-week low of $3.12 and a 52-week high of $7.25. The firm has a 50-day moving average price of $6.17 and a 200-day moving average price of $5.30.

Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings data on Wednesday, March 1st. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.07. Analysts predict that Kindred Biosciences Inc will post ($1.42) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Kindred Biosciences (NASDAQ:KIN)

var userip;Your IP Address: document.write(userip);

Separately, Feltl & Co. reaffirmed a “strong-buy” rating on shares of Kindred Biosciences in a research report on Tuesday, January 3rd.

Several large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in shares of Kindred Biosciences by 6.0% in the fourth quarter. Renaissance Technologies LLC now owns 351,600 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 20,000 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Kindred Biosciences by 5,283.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,334,953 shares of the biopharmaceutical company’s stock worth $5,674,000 after buying an additional 1,310,155 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of Kindred Biosciences by 6,913.3% in the third quarter. Wells Fargo & Company MN now owns 209,627 shares of the biopharmaceutical company’s stock worth $1,046,000 after buying an additional 206,638 shares in the last quarter. 66.01% of the stock is owned by institutional investors and hedge funds.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

5 Day Chart for NASDAQ:KIN

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.